Signals mentioning The Derma Co.
- Honasa Consumer guides to ~30% Q1 FY27 growth, led by Mamaearth and younger brands
- Honasa Consumer projects ~30% revenue growth in Q1 FY27, double-digit margins hold
- Honasa Consumer Guides 30% Q1 FY27 Revenue Growth, Targets ₹5,500 Cr by FY31
- Honasa guides to ~30% Q1 FY27 revenue growth, double-digit operating margins
- Honasa pivots from Mamaearth-only D2C to multi-brand FMCG play targeting HUL, P&G, Marico
- Honasa pushes beyond Mamaearth to challenge HUL, P&G and Marico with multi-brand FMCG play
- Amazon Beautyverse 2026: Vitamin C searches up 35X, men's skincare grows 1.3X in India
- Sofina Ventures Trims Honasa Stake With ₹177 Cr Bulk Deal at ₹424/Share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Smytten opens 9th MINIS store in Hyderabad, targets 50 South India outlets by 2027
- Honasa buys 58% of Fluence Pharma at ₹135 cr, pushes Mamaearth parent into nutraceuticals
- Honasa buys 58% of Fluence Pharma for ₹135 Cr, enters nutraceuticals via Honasa Health
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000 cr nutraceuticals market
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals category
- Honasa Consumer to acquire 58% of Fluence Pharma at Rs 135 cr EV, enters Rs 16,000 cr supplements market
- Honasa Buys 58% of Fluence Pharma for ₹135 Cr, Launches Honasa Health for Nutraceuticals
- Lenskart slips 2.4% on ADIA ₹1,960 Cr exit; Honasa hits 52-week high on FY31 ₹5,500 Cr plan
- Honasa eyes ₹5,500 cr by FY31 as Q4 revenue jumps 23% and margins recover